US20070265283A1 - Xanthine Oxidase Inhibitor - Google Patents
Xanthine Oxidase Inhibitor Download PDFInfo
- Publication number
- US20070265283A1 US20070265283A1 US11/829,286 US82928607A US2007265283A1 US 20070265283 A1 US20070265283 A1 US 20070265283A1 US 82928607 A US82928607 A US 82928607A US 2007265283 A1 US2007265283 A1 US 2007265283A1
- Authority
- US
- United States
- Prior art keywords
- isobu
- carbon atoms
- group
- mmol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C([2*])C=C(C2=NC3=C(C2)[Y]=CC=C3)C=C1.[3*]C Chemical compound [1*]C1=C([2*])C=C(C2=NC3=C(C2)[Y]=CC=C3)C=C1.[3*]C 0.000 description 7
- JAXMOISNXFTVJN-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=NC(C)=C(C(=O)O)S2)=CC=C1OCC(C)C.[C-]#[N+]C1=CC(N2C=C(C(=O)O)C=N2)=CC=C1OCC(C)(C)C.[C-]#[N+]C1=CC=CC(C2=CC=C(C3=NN=NN3)C=C2)=C1 Chemical compound [C-]#[N+]C1=CC(C2=NC(C)=C(C(=O)O)S2)=CC=C1OCC(C)C.[C-]#[N+]C1=CC(N2C=C(C(=O)O)C=N2)=CC=C1OCC(C)(C)C.[C-]#[N+]C1=CC=CC(C2=CC=C(C3=NN=NN3)C=C2)=C1 JAXMOISNXFTVJN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to a xanthine oxidase inhibitor.
- the hyperuricemia causes gout and renal insufficiency and is also considered to be a factor causing coronary disease. Furthermore, the hyperuricemia is suggested to closely relate to the development of diseases of adults such as hypertension. Therefore, treatment of the hyperuricemia can be effective not only for treating gout but also for preventing various diseases relating to daily nutrition and the advancement of age.
- the hyperuricemia is treated using an inhibitor for inhibiting production of uremic acid such as allopurinol and an accelerator for uricotelism such as benzbromalone.
- an inhibitor for inhibiting production of uremic acid such as allopurinol
- an accelerator for uricotelism such as benzbromalone.
- allopurinol causes side effects such as lesion, hepatopathy, and myelogenetic troubles.
- the allopurinol and its metabolic product (oxypurinol) are excreted from the kidneys.
- uric acid decreases
- the excretion of these compounds also decreases and the concentrations of these compounds in blood increase. Therefore, the chance of causing side effects increases.
- the present inventors have discovered that compounds of the below-mentioned formula (I) containing a bicyclic condensed hetero ring have a xanthine oxidase inhibiting effect.
- the present invention has been completed based on this discovery.
- the present invention has an object: to provide compounds of the below-mentioned formula (I) which have a xanthine oxidase (XOD) inhibiting effect.
- R 1 represents an alkyl group having 1-8 carbon atoms, an alkyl group substituted with 1-3 halogen atoms, OR 4 , CO 2 R 5 , or S(O) n R 6 ; wherein R 4 is hydrogen, or an alkyl group having 1-8 carbon atoms, an aralkyl group having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms, an alkylcarbonyl group having 2-9 carbon atoms, an arylcarbonyl group having an aryl moiety of 6-10 carbon atoms, an aralkylcarbonyl group having an aryl moiety of 6-10 carbon atoms and an alkylcarbonyl moiety of 2-5 carbon atoms or an aryl group having 6-10 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro and cyano; each of R 5 and R 6 is hydrogen or an alkyl group having 1-8 carbon atom
- R 2 is hydrogen, halogen, nitro, cyano, formyl, an alkyl group having 1-8 carbon atoms, an alkyl group having 1-8 carbon atoms which is substituted with one to three halogens, or CO 2 R 7 wherein R 7 has the same meaning as R 5 above;
- R 3 is hydrogen, halogen, hydroxyl, amino, CO 2 R 8 , PO 3 H, PO(OH)(OR 9 ), S(O) m R 10 , or an alkyl group having 1-8 carbon atoms or an alkylaminocarbonyl group having alkyl of 1-8 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; wherein each of R 8 , R 9 , and R 10 has the same meaning as R 5 above; m has the same meaning as n above;
- X is NR 11 , oxygen, or sulfur, wherein R 11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; and
- each of Y and Z is CR 12 or nitrogen, wherein R 12 has the same meaning as R 3 above.
- the invention relates to a xanthine oxidase inhibitor containing a compound of the formula (I) or a salt thereof as an active component.
- the invention relates to an agent for treating hyperuricemia containing a compound of the formula (I) or a salt thereof as an active component.
- Examples of the alkyl groups having 1-8 carbon atoms for R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 11 in the formula (I) include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and pentyl.
- Examples of the alkyl groups having 1-8 carbon atoms for R 1 and R 2 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and pentyl which are substituted with one to three fluorines, chlorines, or bromines.
- Examples of the aralkyl groups having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms for R 4 , R 5 and R 6 include benzyl and phenethyl.
- alkylcarbonyl groups having 2-9 carbon atoms for R 4 examples include acetyl and propionyl.
- arylcarbonyl groups having an aryl moiety of 6-10 carbon atoms include benzoyl.
- aralkylcarbonyl groups having an aryl moiety of 6-10 carbon atoms and an alkylcarbonyl moiety of 2-5 carbon atoms include benzylcarbonyl.
- Examples of the aryl groups having 6-10 carbon atoms for R 4 , R 5 and R 6 include phenyl and naphthyl.
- Examples of the halogen substituents for R 2 , R 3 , R 4 , R 5 , R 6 , or R 11 include fluorine, chlorine, and bromine.
- Examples of the alkylaminocarbonyls having an alkyl moiety of 1-8 carbon atoms include methylaminocarbonyl.
- the compound of the formula (I) can be in the form of a pharmacologically acceptable salt.
- R 5 , R 7 , or R 8 is an alkali metal such as sodium, potassium, or lithium.
- the benzamide derivative of the formula (c) can be obtained by reacting a benzoic acid derivative of the formula (a) with an aniline derivative of the formula (b).
- the reaction can be carried out in the conventional manner for the formation of an amide compound.
- a benzoic acid derivative of the formula (a) is first converted into an acid chloride using thionyl chloride or oxalyl chloride, and then the acid chloride is reacted with an aniline derivative of the formula (b) in the presence of a solvent such as water or THF and in the presence or absence of, a base such as sodium hydrogen carbonate or triethylamine.
- a benzoic acid derivative of the formula (a) is reacted with an aniline derivative of the formula (b) in the presence of a condensing agent such as DDC or WSC—HCl.
- the benzamide derivative of the formula (f) can be obtained by reacting a benzoic acid derivative of the formula (a) with an aniline derivative of the formula (e).
- the amide forming reaction can be carried out in the same manner as described in the Synthesis process 1.
- a benzoic thioamide derivative of the formula (g) can be prepared from a benzoic amide of the formula (f) by treatment with Lawesson's reagent.
- the thiobenzamide derivative of the formula (g) is then treated with potassium ferricyanide and sodium hydride, to give a compound of the invention represented by the formula (h).
- the xanthine oxidase inhibiting action (in vitro test) of the compound of the invention was confirmed by measuring inhibition of oxidation of xanthine by xanthine oxidase, as described in Example 13. As is clear from Table 20, the compounds of the invention show excellent xanthine oxidase inhibiting action.
- the xanthine oxidase inhibiting action was further confirmed in vivo tests by measuring the uric acid concentration in a plasma obtained from mouse into which the compound of the invention had been orally administered. See Example 1-B, Table 21.
- the compounds of the invention having the formula (I) are employable for preventing or treating hyperuricemia and gout.
- the compound of the invention can be administered into human beings by appropriate administration methods such as oral administration and parenteral administration.
- the compounds of the invention can be prepared in the form of known pharmaceutical preparations such as pellets, granules, powders, capsules, suspensions, injections, and suppositories.
- a conventionally employed excipients, disintegrators, binder, lubricants, dyes, diluents, or the like are employed.
- the excipient may be lactose, D-mannitol, crystalline cellulose, or glucose.
- the disintegrator may be starch or carboxymethylcellulose calcium (CMC—Ca).
- the lubricant may be magnesium stearate or talc.
- the binder may be hydroxypropylcellulose (HPC), gelatin, or polyvinylpyrrolidone (PVP).
- the adult dosage of the compound of the invention is approximately 0.1 to 100 mg/day when it is administered in the form of an injection, and approximately 1 to 2,000 mg/day when it is orally administered.
- the dosage can be adjusted depending on age and clinical conditions.
- Methyl 4-isobutyloxy-3-nitrobenzoate (2.50 g, 9.87 mmol) was dissolved in a mixture of methanol (10 mL) and 25 THF (10 mL). After addition of 2M aqueous sodium hydroxide (7.5 mL, 15.0 mmol), the solution was stirred for 18 hours at room temperature. The solvent was distilled off under reduced pressure, and were added to the residue water (20 mL) and 3M aqueous hydrochloric acid to adjust 30 the solution to pH 1. The precipitated crystalline product was collected by filtration. The crystalline product washed with water (20 mL ⁇ 2) and dried at 50° C. for 4 hours under reduced pressure, to give 2.31 g (yield 98%) of the desired compound in the form of a white crystalline product.
- 4,5-Diamino-6-hydroxypyrimidine (527 mg, 4.18 mmol) was added to an aqueous suspension of sodium hydrogen carbonate (3.15 g, 41.8 mmol) in water (10 mL) under cooling with ice. Subsequently, a solution of 4-isobutoxy-3-nitrobenzoyl chloride (1.08 g, 4.18 mmol) in ethyl acetate (10 mL) was added. The resulting mixture was stirred for 3 hours under cooling with ice, made acetic by addition of 6 M hydrochloric acid, placed under reduced pressure at room temperature to distill ethyl acetate off, and stirred for 30 min. at room temperature. The precipitated solid product was collected by filtration, washed successively with water and diethyl ether, and dried successively in air and reduced pressure, to give 963 mg (yield 69%) of the desired compound in the form of a powdery product.
- 1,2-Phenylenediamine (1.09 g, 10.1 mmol) was dissolved in THF (20 mL). The solution was cooled with ice water, and to the cooled solution was dropwise added to a solution of 4-isobutoxy-3-nitrobenzoyl chloride (1.00 mmol) in THF (3 mL) for more than 30 min. The mixture was then stirred for 3 hours under cooling with ice-water. The solvent was distilled off under reduced pressure. The residue was suspended in water (20 mL) and stirred for 30 min., at room temperature. The obtained crystalline product was collected by filtration, washed with water (5 mL ⁇ 3), and dried at room temperature under reduced pressure, to give 291 mg (yield 88%) of the desired amide product in the form of a pale yellow crystalline product.
- the amide product (165 mg, 0.50 mmol) and phosphoryl chloride (3.0 mL) were together heated under reflux for 3 hours, and then allowed to stand and cooled to room temperature.
- the reaction mixture was poured into ice-water (50 mL), and the aqueous mixture was stirred for 30 min.
- the obtained crystalline product was collected by filtration, washed with water (5 mL ⁇ 5), and dried at room temperature under reduced pressure, to give 142 mg (yield 91%) of the desired compound in the form of a pale yellow crystalline product.
- IR (KBr) cm ⁇ 1 2962, 2933, 1624, 1527, 1506, 1489, 1470, 1350, 1273, 1244, 1169, 1007.
- the precipitated solid product was collected by filtration and dried in air, to give 20 mg (yield 74%) of the desired compound in the form of a yellow powder product.
- the obtained amide product (225 mg) was heated to 185° C. for 15 min. The heated product was allowed to stand to room temperature.
- 3-Aminosalicylic acid (690 mg, 4.51 mmol), methanol 5 (45 mL), and conc. sulfuric acid (0.9 mL) were mixed, and heated for 55 hours under reflux. The methanol was distilled off under reduced pressure. To the residue was added cooled water. The aqueous residue was made alkaline by addition of aqueous saturated sodium hydrogen carbonate under cooling with ice. Thus precipitated crystalline product were collected by filtration, washed with two portions of water, and dried in vacuo at 40° C. for 40 min., to give 710 mg of a pale pink crystalline product. The product was suspended in chloroform (35 mL), and insolubles were removed by filtration.
- the ethyl acetate portion was successively washed with 2M hydrochloric acid, water, aqueous saturated sodium hydrogen carbonate, and aqueous saturated brine, and dried over sodium sulfate.
- the solvent was distilled off under reduced pressure, to give 320 mg of a brown oil.
- the obtained oil was subjected to silica gel column chromatography. The oil washed from the column with ethyl acetate/hexane (1/4) and then eluted using ethyl acetate/hexane (1/2), to give 115 mg (yield 27.4%) of the desired compound in the form of a white crystalline product.
- Methyl 2-(4-isobutoxy-3-nitrophenyl)benzoxazole-7-carboxylate 22 mg, 0.06 mmol was suspended in methanol (1.8 mL). Tetrahydrofuran (2.4 mL) and 1M NaOH (0.6 mL) were successively added to the suspension, and the mixture was stirred at 50° C. for 2 hours. A small amount of insoluble was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was suspended in water, made acidic by addition of 2M hydrochloric acid (0.6 mL), and extracted with ethyl acetate.
- the ethyl acetate portion washed successively with water (500 mL ⁇ 2) and aqueous saturated brine (200 mL), dried over anhydrous sodium sulfate, and placed under reduced pressure to distill the solvent off.
- the resulting crystalline product was dissolved in ethyl acetate (50 mL) under heating. The mixture was kept hot, while hexane (100 mL) was added to the mixture. The hexane solution was stirred and cooled to room temperature, and further stirred for 10 min. under cooling with ice.
- the precipitated crystalline product was collected by filtration, washed successively with ethyl acetate/hexane (1/5, 60 mL) mixture and hexane (500 mL), and dried in air, to give 20.8 g (yield 33%) of the desired compound in the form of a pale yellow crystalline product.
- Ethyl 3-cyano-4-isobutyloxybenzoate (20.0 g, 80.9 mmol) was dissolved in a mixture of ethanol (100 mL) and THF (100 mL). Aqueous 2M sodium hydroxide (45 mL, 90.0 mmol) was added to the resulting solution, and the mixture was stirred at 30° C. for 4 hours. The solvent was distilled off under reduced pressure. Water (100 mL) was added to the residue and further aqueous 2M hydrochloric acid to obtain an aqueous mixture of pH 1. The precipitated crystalline product was collected by filtration, washed with water (200 mL ⁇ 2), and dried in air, to give 17.5 g (yield 99%) of the desired compound in the form of a white crystalline product.
- Oxalyl chloride (889 mg, 7.0 mmol) was dropwise added to a solution of 3-cyano-4-isobutyloxybenzoic acid (767 mg, 3.5 mmol) in dichloromethane (10 mL) under cooling with ice. Subsequently, a catalytic amount of DMF was added. The mixture was then stirred for one hour at room temperature, heated under reflux for 3 hours, and placed under reduced pressure to distill the solvent off. Toluene was added to the residue and the solvent was distilled off under reduced pressure. THF (10 mL) was added to the residue.
- 3-Nitrobenzoic anhydride (9.65 g, 50 mmol) was divided into three portions and added by portions to aqueous ammonia (28%) under cooling with ice. The mixture was stirred at 60° C. for 12 hours, and placed under reduced pressure to distill the solvent off. The residue was made acidic by addition of aqueous 12M hydrochloric acid. The precipitated crystalline product was collected by filtration, washed with water, and dried in air, to give 9.86 g (yield 94%) of the desired compound in the form of a white crystalline product.
- Ethane thiol (0.45 mL, 6.08 mmol) was added to lithium metal (14 mg, 2.02 mmol), and the mixture was stirred for one hour at room temperature.
- dry DMF 5 mL
- 2-(3-cyano-4-isobutyloxyphenyl)-7-methoxy-1,3-benzothiazole 150 mg, 0.44 mmol.
- the resulting mixture was stirred at 80° C. for 8.5 hours, cooled to room temperature, and, after addition of icewater (10 mL), made to pH 7 by addition of aqueous 1M hydrochloric acid.
- the mixture was then extracted with ethyl acetate (20 mL).
- test compound was dissolved in dimethylsulfoxide and diluted with 50 mM phosphate buffer (pH 7.5), to give a solution of a predetermined concentration
- Inhibition ratio(%) [1 ⁇ ( B ⁇ C )/( A ⁇ C )] ⁇ 100
- the compounds of the present invention show a xanthine oxidase inhibiting action superior to allopurinol.
- ICR mouse Japan Charles River Co., Ltd., 6 W was employed as test animal.
- One group comprised mice, and a vehicle control group was set for each experiment.
- test compound was suspended in aqueous 0.50 methylcellulose solution to for administration.
- Dosage is 3 mg/10 mL/kg for each of the control groups and all test groups.
- the administration was made by single oral administration.
- test compound was orally administered once, and the whole blood was collected from main artery in the presence of heparin after one hour. From the collected whole blood was separated plasma in the conventional manner, and the plasma was subjected to measurement of uric acid value by the enzyme method by means of an automatic analytical apparatus (HITACHI 7060E).
- HITACHI 7060E automatic analytical apparatus
- Inhibition ratio(%) (100 ⁇ A/B ) ⁇ 100
- A average uric acid value in plasma of the group into which the test compound was administered.
- the compounds of the present invention show a significant xanthine oxidase inhibiting action even in the experiment of in vivo.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention relates to compounds of the following formula (I) or their salts:
in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.
in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.
Description
- The present invention relates to a xanthine oxidase inhibitor.
- The hyperuricemia causes gout and renal insufficiency and is also considered to be a factor causing coronary disease. Furthermore, the hyperuricemia is suggested to closely relate to the development of diseases of adults such as hypertension. Therefore, treatment of the hyperuricemia can be effective not only for treating gout but also for preventing various diseases relating to daily nutrition and the advancement of age.
- Presently, the hyperuricemia is treated using an inhibitor for inhibiting production of uremic acid such as allopurinol and an accelerator for uricotelism such as benzbromalone. However, it is well known that allopurinol causes side effects such as lesion, hepatopathy, and myelogenetic troubles. The allopurinol and its metabolic product (oxypurinol) are excreted from the kidneys. However, if the excretion of uric acid decreases, the excretion of these compounds also decreases and the concentrations of these compounds in blood increase. Therefore, the chance of causing side effects increases.
- It is reported that benzbromalone also causes hepatopathy. Accordingly, it is desired to develop new pharmaceuticals so that the practitioners can select more appropriate pharmaceuticals with less side effects.
-
- The present inventors have discovered that compounds of the below-mentioned formula (I) containing a bicyclic condensed hetero ring have a xanthine oxidase inhibiting effect. The present invention has been completed based on this discovery.
- There are known, as compounds structurally analogous to the compounds of the invention, 2-phenylbenzazole compounds (in Japanese Patent Provisional Publication (Toku-15 hyo) 11-501024) and 2-phenylbenzimidazole compounds (in Japanese Patent Provisional Publication 56-5465). The former compounds have an amino group in the 4th position of the benzene ring and show an antitumor effect, while the latter compounds have 2-hydroxy-3-N-substituted aminopropoxy group in the 4th position of the benzene ring and show a hypotension inducing effect. Accordingly, these compounds differ from the compounds of the invention in their structures and pharmacological effects.
- The present invention has an object: to provide compounds of the below-mentioned formula (I) which have a xanthine oxidase (XOD) inhibiting effect.
-
- R1 represents an alkyl group having 1-8 carbon atoms, an alkyl group substituted with 1-3 halogen atoms, OR4, CO2R5, or S(O)nR6; wherein R4 is hydrogen, or an alkyl group having 1-8 carbon atoms, an aralkyl group having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms, an alkylcarbonyl group having 2-9 carbon atoms, an arylcarbonyl group having an aryl moiety of 6-10 carbon atoms, an aralkylcarbonyl group having an aryl moiety of 6-10 carbon atoms and an alkylcarbonyl moiety of 2-5 carbon atoms or an aryl group having 6-10 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro and cyano; each of R5 and R6 is hydrogen or an alkyl group having 1-8 carbon atoms, an aralkyl group having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms, or an aryl group having 6-10-carbon atoms which may have substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; and n is an integer of 0 to 2;
- R2 is hydrogen, halogen, nitro, cyano, formyl, an alkyl group having 1-8 carbon atoms, an alkyl group having 1-8 carbon atoms which is substituted with one to three halogens, or CO2R7 wherein R7 has the same meaning as R5 above;
- R3 is hydrogen, halogen, hydroxyl, amino, CO2R8, PO3H, PO(OH)(OR9), S(O)mR10, or an alkyl group having 1-8 carbon atoms or an alkylaminocarbonyl group having alkyl of 1-8 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; wherein each of R8, R9, and R10 has the same meaning as R5 above; m has the same meaning as n above;
- X is NR11, oxygen, or sulfur, wherein R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; and
- each of Y and Z is CR12 or nitrogen, wherein R12 has the same meaning as R3 above.
- In addition, the invention relates to a xanthine oxidase inhibitor containing a compound of the formula (I) or a salt thereof as an active component.
- Furthermore, the invention relates to an agent for treating hyperuricemia containing a compound of the formula (I) or a salt thereof as an active component.
- The invention is further described below in detail. Examples of the alkyl groups having 1-8 carbon atoms for R1, R2, R3, R4, R5, R6 and R11 in the formula (I) include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and pentyl.
- Examples of the alkyl groups having 1-8 carbon atoms for R1 and R2 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and pentyl which are substituted with one to three fluorines, chlorines, or bromines. Examples of the aralkyl groups having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms for R4, R5 and R6 include benzyl and phenethyl.
- Examples of the alkylcarbonyl groups having 2-9 carbon atoms for R4 include acetyl and propionyl.
- Examples of the arylcarbonyl groups having an aryl moiety of 6-10 carbon atoms include benzoyl.
- Examples of the aralkylcarbonyl groups having an aryl moiety of 6-10 carbon atoms and an alkylcarbonyl moiety of 2-5 carbon atoms include benzylcarbonyl.
- Examples of the aryl groups having 6-10 carbon atoms for R4, R5 and R6 include phenyl and naphthyl.
- Examples of the halogen substituents for R2, R3, R4, R5, R6, or R11 include fluorine, chlorine, and bromine. Examples of the alkylaminocarbonyls having an alkyl moiety of 1-8 carbon atoms include methylaminocarbonyl.
-
- (1) Preferred is a compound of the formula (I) in which R1 is OR4, and a salt thereof.
- (2) Also preferred is a compound of the formula (I) in which R1 is an alkoxy group having 1-5 carbon atoms, and a salt thereof.
- (3) Also preferred is a compound of the formula (I) in which R1 is isobutoxy and a salt thereof.
- (4) Also preferred is a compound of the formula (I) in which R2 is nitro, cyano, halogen, or carboxyl, and a salt thereof.
- (5) Also preferred is a compound of the formula (I) or according to (1) to (3) above in which R3 is nitro or cyano, and a salt thereof
- (6) Also preferred is a compound of the formula (I) or according to (1) to (5) above in which R3 is hydrogen, amino, hydroxyl, halogen, or carboxyl, and a salt thereof.
- (7) Also preferred is a compound of the formula (I) or according to (1) to (6) above in which X is NH or oxygen, and each of Y and Z is nitrogen, and a salt thereof.
- (8) Also preferred is a compound of the formula (I) or according to (1) to (6) above in which X is sulfur, oxygen or NH, and Y is CH, C—OH or C—CO2H, and Z is CH, and a salt thereof.
- (9) Also preferred is a compound of the formula (I) or according to (1) to (6) above in which X is NH, and at least one of Y and Z is nitrogen and another is CH, and a salt thereof.
- The compound of the formula (I) can be in the form of a pharmacologically acceptable salt. For instance, R5, R7, or R8 is an alkali metal such as sodium, potassium, or lithium.
-
- The benzamide derivative of the formula (c) can be obtained by reacting a benzoic acid derivative of the formula (a) with an aniline derivative of the formula (b).
- The reaction can be carried out in the conventional manner for the formation of an amide compound. For instance, a benzoic acid derivative of the formula (a) is first converted into an acid chloride using thionyl chloride or oxalyl chloride, and then the acid chloride is reacted with an aniline derivative of the formula (b) in the presence of a solvent such as water or THF and in the presence or absence of, a base such as sodium hydrogen carbonate or triethylamine. Otherwise, a benzoic acid derivative of the formula (a) is reacted with an aniline derivative of the formula (b) in the presence of a condensing agent such as DDC or WSC—HCl.
- The resulting benzoic amide of the formula (c) is reacted with phosphorus oxychloride or heated to give the compound of the invention represented by the formula (d).
[Synthesis Process 2—in the Case of :X═S]
[in which R is hydrogen or halogen such as chlorine, and R1, R2, R3, Y and Z are the same as those identified above. - The benzamide derivative of the formula (f) can be obtained by reacting a benzoic acid derivative of the formula (a) with an aniline derivative of the formula (e).
- The amide forming reaction can be carried out in the same manner as described in the Synthesis process 1.
- A benzoic thioamide derivative of the formula (g) can be prepared from a benzoic amide of the formula (f) by treatment with Lawesson's reagent.
- The thiobenzamide derivative of the formula (g) is then treated with potassium ferricyanide and sodium hydride, to give a compound of the invention represented by the formula (h).
- Other compounds represented by the formula (I) can be prepared in analogous manners.
- Examples of the compounds of the invention are illustrated in the following tables 1 to 19.
- (1) Examples of the following compounds having NR11 for X are set forth in the following tables 1 to 7.
TABLE 1 R3 position R1 R2 4- 4-6 R11 Y Z O-isoBu NO2 H H H N N O-isoBu NO2 Cl H H N N O-isoBu CO2H Cl H H N N O-isoBu Cl Cl H H N N O-isoBu NO2 Cl H Me N N O-isoBu NO2 H Cl H N N O-isoBu CN Cl H H N N O-isoPr CN Cl H H N N O-isoBu NO2 OH H H N N O-isoBu CO2H OH H H N N O-isoBu CHO OH H H N N O-isoBu NO2 OH H Me N N O-isoPr NO2 H OH H N N O-isoBu CN OH H H N N -
TABLE 2 R3 Position R1 R2 4- 6- R11 Y Z O-isoPr CN OH H H N N O-isoBu NO2 NH2 H H N N O-isoBu CO2H NH2 H H N N O-isoBu CF3 NH2 H H N N O-isoBu CHO NH2 H H N N O-isoBu NO2 NH2 H Me N N O-isoPr NO2 H NH2 H N N O-Et NO2 NH2 H H N N O-Me NO2 NH2 H H N N CF3 NO2 NH2 H H N N IsoPr NO2 NH2 H H N N OCH2CO2Et NO2 NH2 H H N N O-isoBu CN NH2 H H N N O-isoPr CN H NH2 H N N -
TABLE 3 R3 Position R1 R2 4- 6- R11 Y Z O-Et CN NH2 H H N N O-Me CN NH2 H H N N CF3 CN NH2 H H N N IPr CN NH2 H H N N OCH2CO2 CN NH2 H H N N O-isoBu NO2 H H H N CH O-isoBu CO2H H H H N CH O-isoBu F H H H N CH O-isoBu NO2 H H Me N CH O-isoPr NO2 H H H N CH 0-isoBu CN H H H N CH 0-isoPr CN H H H N CH O-isoBu NO2 H H H N COH O-isoBu NO2 H H H N CNH2 -
TABLE 4 R3 Position R1 R2 4- 6- R11 Y Z O-isoBu NO2 H H H N CCO2H O-isoBu NO2 H H H CH N O-isoBu CO2H H H H CH N O-isoBu CF3 H H H CH N O-isoBu NO2 H H Me CH N O-isoPr NO2 H H H CH N O-isoBu CN H H H CH N O-isoPr CN H H H CH N O-isoBu NO2 H H H CH CH O-isoBu CO2H H H H CH CH 0-isoBu Cl H H H CH CH 0-isoBu NO2 H H Me CH CH O-isoPr NO2 H H H CH CH O-isoBu CN H H H CH CH -
TABLE 5 R3 Position R1 R2 4- 6- R11 Y Z O-isoPr CN H H H CH CH O-isoBu NO2 OH H H CH CH O-isoBu CO2H OH H H CH CH O-isoBu CHO OH H H CH CH O-isoBu NO2 OH H Me CH CH O-isoPr NO2 H OH H CH CH O-isoBu CH OH H H CH CH O-isoBu NO2 H H H CH COH O-isoBu NO2 H H H H CNH2 O-isoBu NO2 H H H CH CCO2H O-isoBu NO2 H H H COH N O-isoBu NO2 H H H COH CH O-isoBu CN H H H COH CH O-isoBu CO2H H H H COH CH -
TABLE 6 R3 Position R1 R2 4- 6- R11 Y Z O-isoBu NO2 H H H CNH2 N O-isoBu NO2 H H H CNH2 CH O-isoBu NO2 H H H CCO2Me N O-isoBu NO2 H H H CCO2ME CH O-isoBu NO2 H H H CCO2H N O-isoBu NO2 H H H CCO2H CH O-isoBu CO2H H H H CCO2H CH O-isoBu F H H H CCO2H CH O-isoBu CHO H H H CCO2H CH O-isoBu NO2 H H Me CCO2H CH O-isoPr NO2 H H H CCO2H XH O-Et NO2 H H H CCO2H CH O-Me NO2 H H H CCO2H CH CF3 NO2 H H H CCO2H CH -
TABLE 7 R3 Position R1 R2 4- 6- R11 Y Z isoPr NO2 H H H CCO2H CH OCH2CO2Et NO2 H H H CCO2H CH O-isoBu CN H H H CCO2H CH O-isoBu CO2H H H H CCO2H CH O-isoBu Cl H H H CCO2H CH O-isoBu CF3 H H Me CCO2H CH O-isoPr CN H H H CCO2H CH O-Et CN H H H CCO2H CH CF3 CN H H H CCO2H CH IsoPr CN H H H CCO2H CH OCH2CO2Et CN H H H CCO2H CH O-isoBu NO2 H H H CPO3H N O-isoBu NO2 H H H CPO3H CH O-isoBu NO2 H H H CCONHMe N O-isoBu NO2 H H H CCONHMe CH - (2) Examples of the following compounds having 0 for X are set forth in the following tables 8 to 13.
TABLE 8 R3 Position R1 R2 4- 6- Y Z O-isoBu NO2 H H N N O-isoBu NO2 Cl H N N O-isoBu Cl Cl H N N O-isoPr NO2 Cl H N N O-isoBu CN Cl H N N O-isoPr CN Cl H N N O-isoBu NO2 OH H N N O-isoBu CHO OH H N N O-isoPr NO2 OH H N N O-isoBu CN OH H N N O-isoPr CN OH H N N O-isoBu NO2 NH2 H N N O-isoBu CO2H NH2 H N N O-isoBu CF3 NH2 H N N -
TABLE 9 R3 Position R1 R2 4- 6- Y Z O-isoBu CHO NH2 H N N O-isoPr NO2 H NH2 N N O-Et NO2 NH2 H N N O-Me NO2 NH2 H N N CF3 NO2 NH2 H N N IsoPr NO2 NH2 H N N OCH2CO2Et NO2 NH2 H N N O-isoBu CN NH2 H N N O-isoPr CN H NH2 N N O-Et CN NH2 H N N O-Me CN NH2 H N N CF3 CN NH2 H N N IsoPr CN NH2 H N N OCH2CO2Et CN NH2 H N N -
TABLE 10 R3 Position R1 R2 4- 6- Y Z O-isoBu NO2 H H N CH O-isoBu F H H N CH O-isoPr NO2 H H N CH O-isoBu CN H H N CH O-isoPr CN H H N CH O-isoBu NO2 H H N COH O-isoBu NO2 H H N CNH2 O-isoBu NO2 H H N CCO2H O-isoBu NO2 H H CH N O-isoBu CF3 H H CH N O-isoPr NO2 H H CH N O-isoBu CN H H CH N O-isoPr CN H H CH N O-isoBu NO2 H H CH CH -
TABLE 11 R3 Position R1 R2 4- 6- Y Z O-isoBu Cl H H CH CH O-isoPr NO2 H H CH CH O-isoBu CN H H CH CH O-isoPr CN H H CH CH O-isoBu NO2 OH H CH CH O-isoBu CO2H OH H CH CH O-isoBu COH OH H CH CH O-isoPr NO2 H OH CH CH O-isoBu CN OH H CH CH O-isoBu NO2 H H CH COH O-isoBu NO2 H H CH CNH2 O-isoBu NO2 H H CH CCO2H O-isoBu NO2 H H COH N O-isoBu NO2 H H COH CH -
TABLE 12 R3 Position R1 R2 4- 6- Y Z O-isoBu CN H H COH CH O-isoBu NO2 H H CNH2 N O-isoBu NO2 H H CNH2 CH O-isoBu NO2 H H CCO2Me N O-isoBu NO2 H H CCO2Me CH O-isoBu NO2 H H CCO2H N O-isoBu NO2 H H CCO2H CH O-isoBu CO2H H H CCO2H CH O-isoBu F H H CCO2H CH O-isoBu CHO H H CCO2H CH O-isoPr NO2 H H CCO2H CH O-Et NO2 H H CCO2H CH O-Me NO2 H H CCO2H CH CF3 NO2 H H CCO2H CH -
TABLE 13 R3 Position R1 R2 4- 6- Y Z IsoPr NO2 H H CCO2H CH OCH2CO2Et NO2 H H CCO2H CH O-isoBu CN H H CCO2H CH O-isoBu CN H H CCO2H CH O-isoBu Cl H H CCO2H CH O-isoPr CN H H CCO2H CH O-Et CN H H CCO2H CH CF3 CN H H CCO2H CH IsoPr CN H H CCO2H CH OCH2CO2Et CN H H CCO2H CH O-isoBu NO2 H H CPO3H N O-isoBu NO2 H H CPO3H CH O-isoBu NO2 H H CCONHMe N O-isoBu NO2 H H CCONHMe CH - (3) Examples of the following compounds having S for X are set forth in the following tables 14 to 19.
TABLE 14 R3 Position R1 R2 4- 6- Y Z O-isoBu NO2 H H N N O-isoBu NO2 Cl H N N O-isoBu Cl Cl H N N O-isoPr NO2 Cl H N N O-isoBu CN Cl H N N O-isoPr CN Cl H N N O-isoBu NO2 OH H N N O-isoBu CHO OH H N N O-isoPr NO2 OH H N N O-isoBu CN OH H N N O-isoPr CN OH H N N O-isoBu NO2 NH2 H N N O-isoBu CO2H NH2 H N N O-isoBu CF3 NH2 H N N -
TABLE 15 R3 Position R1 R2 4- 6- Y Z O-isoBu CHO NH2 H N N O-isoPr NO2 H NH2 N N O-Et NO2 NH2 H N N O-Me NO2 NH2 H N N CF3 NO2 NH2 H N N isoPr NO2 NH2 H N N OCH2CO2Et NO2 NH2 H N N O-isoBu CN NH2 H N N O-isoPr CN H NH2 N N O-Et CN NH2 H N N O-Me CN NH2 H N N CF3 CN NH2 H N N isoPr CN NH2 H N N OCH2CO2Et CN NH2 H N N -
TABLE 16 R3 Position R1 R2 4- 6- Y Z O-isoBu NO2 H H N CH O-isoBu F H H N CH O-isoPr NO2 H H N CH O-isoBu CN H H N CH O-isoPr CN H H N CH O-isoBu NO2 H H N COH O-isoBu NO2 H H N CNH2 O-isoBu NO2 H H N CCO2H O-isoBu NO2 H H CH N O-isoBu CF3 H H CH N O-isoPr NO2 H H CH N O-isoBu CN H H CH N O-isoPr CN H H CH N O-isoBu NO2 H H CH CH -
TABLE 17 R3 Position R1 R2 4- 6- Y Z O-isoBu Cl H H CH CH O-isoPr NO2 H H CH CH O-isoBu CN H H CH CH O-isoPr CN H H CH CH O-isoBu NO2 CH H CH CH O-isoBu CO2H H H CH CH O-isoBu CHO OH H H CH O-isoPr NO2 H OH CH CH O-isoBu CN OH H CH CH O-isoBu NO2 H H CH COH O-isoBu NO2 H H CH CNH2 O-isoBu NO2 H H CH CCO2H O-isoBu NO2 H H COH N O-isoBu NO2 H H COH CH -
TABLE 18 R3 Position R1 R2 4- 6- Y Z O-isoBu CN H H COH CH O-isoBu NO2 H H CNH2 N O-isoBu NO2 H H CNH2 CH O-isoBu NO2 H H CCO2Me N O-isoBu NO2 H H CCO2Me CH O-isoBu NO2 H H CCO2H N O-isoBu NO2 H H CCO2H CH O-isoBu CO2H H H CCO2H CH O-isoBu F H H CCO2H CH O-isoBu CHO H H CCO2H CH O-isoPr NO2 H H CCO2H CH O-Et NO2 H H CCO2H CH O-Me NO2 H H CCO2H CH CF3 NO2 H H CCO2H CH -
TABLE 19 R3 Position R1 R2 4- 6- Y Z IsoPr NO2 H H CCO2H CH OCH2CO2Et NO2 H H CCO2H CH O-isoBu CN H H CCO2H CH O-isoBu CN H H CCO2H CH O-isoBu Cl H H CCO2H CH O-isoPr CN H H CCO2H CH O-Et CN H H CCO2H CH CF3 CN H H CCO2H CH IsoPr CN H H CCO2H CH OCH2CO2Et CN H H CCO2H CH O-isoBu NO2 H H CPO3H N O-isoBu NO2 H H CPO3H CH O-isoBu NO2 H H CCONHMe N O-isoBu NO2 H H CCONHMe CH - The pharmacological actions of the present invention are described below.
- The xanthine oxidase inhibiting action (in vitro test) of the compound of the invention was confirmed by measuring inhibition of oxidation of xanthine by xanthine oxidase, as described in Example 13. As is clear from Table 20, the compounds of the invention show excellent xanthine oxidase inhibiting action.
- The xanthine oxidase inhibiting action was further confirmed in vivo tests by measuring the uric acid concentration in a plasma obtained from mouse into which the compound of the invention had been orally administered. See Example 1-B, Table 21.
- Accordingly, it is expected that the compounds of the invention having the formula (I) are employable for preventing or treating hyperuricemia and gout.
- The compound of the invention can be administered into human beings by appropriate administration methods such as oral administration and parenteral administration.
- The compounds of the invention can be prepared in the form of known pharmaceutical preparations such as pellets, granules, powders, capsules, suspensions, injections, and suppositories. For the preparations, a conventionally employed excipients, disintegrators, binder, lubricants, dyes, diluents, or the like are employed. The excipient may be lactose, D-mannitol, crystalline cellulose, or glucose. The disintegrator may be starch or carboxymethylcellulose calcium (CMC—Ca). The lubricant may be magnesium stearate or talc. The binder may be hydroxypropylcellulose (HPC), gelatin, or polyvinylpyrrolidone (PVP).
- Generally, the adult dosage of the compound of the invention is approximately 0.1 to 100 mg/day when it is administered in the form of an injection, and approximately 1 to 2,000 mg/day when it is orally administered. The dosage can be adjusted depending on age and clinical conditions.
- The present invention is further described below by the following non-limiting examples.
- 4-Hydroxy-3-nitrobenzoic acid (10.0 g, 54.6 mmol) was suspended in methanol (60 mL). After addition of conc. sulfuric acid (0.1 mL), the suspension was heated overnight under reflux. The methanol was distilled off under reduced pressure. The residue was dissolved in ethyl acetate (40 mL), washed successively with aqueous sodium hydrogen carbonate (20 mL×2) and saturated aqueous brine (20 mL), and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, to give 6.27 g (yield 58%) of the desired compound in the form of a pale brown crystalline product.
- M. p. 72-73° C. 1H NMR (CDCl3, 400 MHz) δ: 3.95 (3H, s), 7.22 (1H, d, J=9 Hz), 8.24 (1H, dd, J=2 Hz, 9 Hz), 8.83 (1H, d, J=2 Hz), 10.89 (1H, s).
- Isobutyl bromide (10.5 mL, 95.8 mmol) was added to a suspension of methyl 4-hydroxy-3-nitrobenzoate (6.26 g, 31.8 mmol) and potassium carbonate (13.2 g, 95.5 mmol) in dry DMF (40 mL). The resulting mixture was stirred at 90° C. for 44 hours and then cooled to room temperature. Subsequently, ice-water (80 mL) was added to the cooled mixture. The precipitated crystalline product was collected by filtration, washed with water (50 mL), and dried for 30 min in air. The dried crystalline product was then washed with hexane (40 mL), and dried in air to give 7.03 g (yield 87%) of the desired compound in the form of a pale orange crystalline product.
- M.p.: 77-77° C.
- 1H NMR (CDCl3, 400 MHz) δ: 1.07 (6H, d, J=7 Hz), 2.1-2.3 (1H, m), 3.93 (2H, d, J=7 Hz), 3.93 (3H, s), 7.09 (1H, 20 d, J=9 Hz), 8.18 (1H, dd, J=2 Hz, 9 Hz), 8.50 (1H, d, J=2 Hz).
- Methyl 4-isobutyloxy-3-nitrobenzoate (2.50 g, 9.87 mmol) was dissolved in a mixture of methanol (10 mL) and 25 THF (10 mL). After addition of 2M aqueous sodium hydroxide (7.5 mL, 15.0 mmol), the solution was stirred for 18 hours at room temperature. The solvent was distilled off under reduced pressure, and were added to the residue water (20 mL) and 3M aqueous hydrochloric acid to adjust 30 the solution to pH 1. The precipitated crystalline product was collected by filtration. The crystalline product washed with water (20 mL×2) and dried at 50° C. for 4 hours under reduced pressure, to give 2.31 g (yield 98%) of the desired compound in the form of a white crystalline product.
- M.p.: 184-186° C.
- 1H NMR (CDCl3, 400 MHz) δ: 1.08 (6H, d, J=6 Hz), 2.1-2.3 (1H, m), 3.95 (2H, d, J=6 Hz), 7.13 (1H, d, J=9 Hz), 8.24 (1H, dd, J=2 Hz, 9 Hz), 8.56 (1H, d, J=2 Hz).
- 4,5-Diamino-6-hydroxypyrimidine (527 mg, 4.18 mmol) was added to an aqueous suspension of sodium hydrogen carbonate (3.15 g, 41.8 mmol) in water (10 mL) under cooling with ice. Subsequently, a solution of 4-isobutoxy-3-nitrobenzoyl chloride (1.08 g, 4.18 mmol) in ethyl acetate (10 mL) was added. The resulting mixture was stirred for 3 hours under cooling with ice, made acetic by addition of 6 M hydrochloric acid, placed under reduced pressure at room temperature to distill ethyl acetate off, and stirred for 30 min. at room temperature. The precipitated solid product was collected by filtration, washed successively with water and diethyl ether, and dried successively in air and reduced pressure, to give 963 mg (yield 69%) of the desired compound in the form of a powdery product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.00 (6H, d, J=6 Hz), 2.0-2.1 (1H, m), 4.03 (2H, d, J=6 Hz), 6.37 (2H, broad, s), 7.45 (1H, d, J=9 Hz), 7.78 (1H, s), 8.22 (1H, dd, J=2 Hz, 9 Hz), 8.44 (1H, d, J=2 Hz), 9.18 (1H, s), 11.70 (1H, s).
- A mixture of 4-amino-6-hydroxy-5-(4-isobutoxy-3-nitrobenzoyl)aminopyridine (354 mg, 1.07 mmol) and phosphorus oxychloride (6 mL) was stirred at. 120° C. for 4.5 hours. Excessive phosphorus oxychloride was distilled off under reduced pressure. The residue was stirred for 30 min., after addition of ice-water. The insolubles (1) were removed by filtration and the filtrate was stirred for 30 min., after addition of aqueous 0.5 M sodium hydroxide (24 mL). The insolubles were then removed by filtration, and the aqueous portion was made acidic by addition of acetic acid. The precipitated solid product was collected by filtration. The collected solid product and the insolubles (2) were combined and subjected to silica gel column chromatography and eluted using ethyl acetate/n-hexane (2/1) to give 45 mg (yield 13%) of the desired compound (A) and 60 mg (yield 17%) of the desired compound (B), both in the form of a pale yellow powdery product.
- (A) 1H NMR (CDCl3-CD3OD, 400 MHz) δ: 1.10 (6H, d, 25 J=7 Hz), 2.2-2.3 (1H, m), 3.98 (2H, d, J=7 Hz), 7.23 (1H, d, J=9 Hz), 8.48 (1H, dd, J=2 Hz, 9 Hz), 8.64 (1H, d, J=2 Hz), 8.74 (1H, s).
- (B) 1H NMR (DMSO-d6, 400 MHz) δ: 1.01 (6H, d, J=7 Hz), 2.1-2.2 (1H, m), 4.07 (2H, d, J=7 Hz), 7.60 (1H, d, J=9 Hz), 7.77 (2H, broad, s), 8.25 (1H, s), 8.32 (1H, dd, J=2 Hz, 9 Hz), 8.55 (1H, d, J=2 Hz).
- FAB-MS (m/e): 330 (M+1).
- A suspension of 8-(4-isobutoxy-3-nitrophenyl)-6-chloropurine (30 mg, 0.086 mmol) in aqueous 2M hydrochloric acid (4.5 mL) was heated to 120° C. for 3 hours under stirring. The suspension was then cooled to room temperature. The precipitated solid product was collected by filtration, washed with water, and dried in air. The dried product was heated to 100° C. after addition of aqueous 2M hydrochloric acid (27 mL). The insolubles were removed while the aqueous portion was still hot. The filtrate was stirred overnight. The precipitated solid product was collected by filtration, washed with water, and dried in air, to give 12 mg (yield 43%) of the desired compound in the form of a yellow powdery product.
- hu 1H NMR (DMSO-d6, 400 MHz) δ: 1.00 (6H, d, J=7 Hz), 2.0-2.2 (1H, m), 4.03 (2H, d, J=6 Hz), 7.55 (1H, d, J=9 Hz), 8.02 (1H, s), 8.39 (1H, dd, J=2 Hz, 9 Hz), 8.65 (1H, d, J=2 Hz), 12.28 (1H, s).
- FAB-MS (m/e): 330 (M+1).
- 1,2-Phenylenediamine (1.09 g, 10.1 mmol) was dissolved in THF (20 mL). The solution was cooled with ice water, and to the cooled solution was dropwise added to a solution of 4-isobutoxy-3-nitrobenzoyl chloride (1.00 mmol) in THF (3 mL) for more than 30 min. The mixture was then stirred for 3 hours under cooling with ice-water. The solvent was distilled off under reduced pressure. The residue was suspended in water (20 mL) and stirred for 30 min., at room temperature. The obtained crystalline product was collected by filtration, washed with water (5 mL×3), and dried at room temperature under reduced pressure, to give 291 mg (yield 88%) of the desired amide product in the form of a pale yellow crystalline product.
- The amide product (165 mg, 0.50 mmol) and phosphoryl chloride (3.0 mL) were together heated under reflux for 3 hours, and then allowed to stand and cooled to room temperature. The reaction mixture was poured into ice-water (50 mL), and the aqueous mixture was stirred for 30 min. The obtained crystalline product was collected by filtration, washed with water (5 mL×5), and dried at room temperature under reduced pressure, to give 142 mg (yield 91%) of the desired compound in the form of a pale yellow crystalline product.
- M.p.: 235-240° C. (decomp.)
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.02 (6H, d, J=6 Hz), 2.0-2.2 (1H, m), 4.07 (2H, d, J=6 Hz), 7.3-7.4 (2H, m), 7.63 (1H, d, J=9 Hz), 7.7-7.8 (2H, m), 8.50 (1H, dd, 25 J=2 Hz, 9 Hz), 8.75 (1H, d, J=2 Hz).
- Sodium hydrogen carbonate (350 mg, 4.17 mmol) was added to a solution of 2,3-diaminopyridine (228 mg, 2.09 mmol) in water (2 mL) under cooling with ice. To the solution was further added a solution of 4-isobutoxy-35 nitrobenzoyl chloride (108 mg, 2.09 mmol) in ethyl acetate (2 mL). The mixture was stirred for 2 hours under cooling with ice. The ethyl acetate was distilled off under reduced pressure, and to the residue was added water. The resulting solid product was collected by filtration, dried in air, subjected to silica gel column chromatography, and eluted using chloroform/methanol (30/1). There was produced 54 mg (yield 41%) of the desired compound in the form of a yellow powdery product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.00 (6H, d, J=7 Hz), 2.0-2.1 (1H, m), 4.04 (2H, d, J=6 Hz), 5.83 (2H, s), 6.60 (1H, dd, J=5 Hz, 7 Hz), 7.48 (1H, J=9 Hz), 7.50 (1H, d, J=5 Hz), 7.81 (1H, broad d, J=5 Hz), 8.25 (1H, broad d, J=9 Hz), 8.52 (1H, broad s), 9.72 (1H, s).
- A mixture of 2-amino-3-(4-isobutoxy-3-nitrobenzoyl)-aminopyridine (40 mg) and phosphorus oxychloride (2 mL) was heated to 120° C. for 8 hours under stirring. Excessive phosphorus oxychloride was distilled off under reduced pressure, and ice water was added to the residue. The precipitated solid product was collected by filtration, washed with water, and dried successively in air and at 60° C. under reduced pressure, to give 42 mg (yield 100%) of the desired compound in the form of a white powdery product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.01 (6H, d, J=7 Hz), 2.1-2.2 (1H, m), 4.06 (2H, d, J=6 Hz), 7.3-7.35 (1H, m), 7.60 (1H, d, J=9 Hz), 8.10 (1H, broad s), 8.40 (1H, broad s), 8.48 (1H, dd, J=2 Hz, 9 Hz), 8.73 (1H, d, J=2 Hz).
- 2-Nitroresorcinol (1.00 g, 6.45 mmol) was dissolved in ethanol (10 mL). The solution was then stirred for 6 hours at room temperature in the presence of 10% Pd/C (340 mg, 0.32 mmol) under hydrogen gas atmosphere. Insolubles were removed by filtration, and the solvent was distilled off under reduced pressure, to give 779 mg (yield 97%) of the desired compound in the form of a brown crystalline product.
- M.P.: 153-155° C. (decomp.)
- 1H NMR (CD3OD/CDCl3=1/20, 400 MHz) δ: 6.37 (2H, d, J=8 Hz), 6.54 (1H, t, J=8 Hz).
- 4-Isobutyloxy-3-nitrobenzoic acid (480 mg, 2.01 mmol) and 2-aminoresorcinol (250 mg, 2.00 mmol) were suspended in dry dichloromethane (12 mL). 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl) (420 mg, 2.19 mmol), dry THF (6 mL) and dry DMF (6 mL) were added to the suspension. The mixture was then stirred for 19 hours at room temperature. Water (40 mL) and chloroform (20 mL) were added, and the organic portion was separated. The organic portion was then washed successively with water (20 mL×2) and aqueous saturated brine (20 mL), dried over anhydrous sodium sulfate, and placed under reduced pressure to distill the solvent off.
- The residue was purified by silica gel column chromatography (methanol/chloroform=1/100) and subsequently crystallized from chloroform/hexane (1/3, 1.6 mL), to give 97 mg (yield 14%) of N-(2,6-dihydroxyphenyl.)-4-isobutyloxy-3-nitrobenzamide in the form of a brown crystalline product.
- Forty mg (0.12 mmol) of the above-obtained product was heated to 225-227° C. for one hour and purified by silica gel column chromatography (ethyl acetate/hexane=1/2), to give 13.6 mg (yield 36%) of the desired compound in the form of a pale yellow crystalline product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.05 (6H, d, J=6 Hz), 2.0-2.2 (1H, m), 4.07 (2H, d, J=7 Hz), 6.79 (1H, dd, J=1 Hz, 7 Hz), 7.1-7.3 (2H, m), 7.59 (1H, d, J=9 Hz), 8.37 (1H, dd, J=2 Hz, 9 Hz), 8.58 (1H, d, J=2 Hz).
- IR (KBr) cm−1: 2962, 2933, 1624, 1527, 1506, 1489, 1470, 1350, 1273, 1244, 1169, 1007.
- FAB-MS (m/e): 329 (M+1).
- A solution of 4-isobutoxy-3-nitrobenzoyl chloride (538 mg, 2.09 mmol) in 1,4-dioxane (2 mL) was dropwise added to a suspension of 4,5,6-triaminopyrimidine sulfate (466 mg, 2.09 mmol) in aqueous 1M sodium hydroxide (4.18 30 mL) under cooling with ice. The resulting mixture was stirred for 4 hours at the same temperature. Water (12 mL) was added to the reaction mixture. The precipitated solid product was collected by filtration, dried in air, and subjected to silica gel column chromatography. The elute using chloroform/methanol (10/1) gave 144 mg (yield 20%) of the desired compound in the form of a yellow powdery product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.00 (6H, d, J=7 Hz), 2.0-2.1 (1H, m), 4.03 (2H, d, J=7 Hz), 5.99 (4H, s), 7.45 10 (1H, d, J=9 Hz), 7.76 (1H, s), 8.23 (1H, dd, =2 Hz, 9 Hz), 8.49 (1H, d, J=2 Hz), 9.26 (1H, s).
- A mixture of 4,6-diamino-5-(4-isobutoxy-3-nitrobenzoyl)aminopyridine (40 mg, 0.115 mmol) and phosphorus oxychloride (2 mL) was heated to 120° C. for 8 hours under stirring. Excessive phosphorus oxychloride was distilled off under reduced pressure. Ice-water was added to the residue. The precipitated solid product was collected by filtration, washed with water, and dried in air. Methanol (1.5 mL) was added to the dried product was added methanol (1.5 mL), and the mixture was stirred for 2 hours at room temperature.
- The precipitated solid product was collected by filtration and dried in air, to give 20 mg (yield 74%) of the desired compound in the form of a yellow powder product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.00 (6H, d, J=6 Hz), 2.0-2.1 (1H, m), 4.08 (2H, d, J=6 Hz), 7.63 (1H, d, J=9 Hz), 8.38 (1H, dd, J=2 Hz, 9 Hz), 8.58 (1H, s), 8.64 (1H, d, J=2 Hz).
- 2,3-diaminophenol (1.86 g, 15.0 mmol) was suspended in dry THF (150 mL). A solution of 4-isobutoxy-3-nitrobenzoyl chloride (2.50 mmol) in THF (10 mL) for a period of more than 30 minutes was dropwise added to the suspension. The resulting mixture was stirred for 3.5 hours under cooling with ice. The solvent was distilled off under reduced pressure. The residue was suspended in water (150 mL) and stirred for one hour at room temperature. The crystalline product was collected by filtration, washed with water (20 mL×5), and dried at room temperature under reduced pressure. The obtained crude product was purified by silica gel column chromatography (methanol/chloroform=1/25), to give 250 mg (yield 29%) of an amide compound in the form of a brown crystalline product.
- The obtained amide product (225 mg) was heated to 185° C. for 15 min. The heated product was allowed to stand to room temperature. The obtained crude product was purified by silica gel column chromatography (ethyl acetate/hexane=1/1), to give 83 mg (yield 39%) of the desired compound in the form of a brown crystalline product.
- M.p.: 244-249° C. (decomp.)
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.01 (6H, d, J=6 Hz), 2.0-2.2 (1H, m), 4.03 (2H, d, J=6 Hz), 6.58 (1H, bs), 6.9-7.1 (2H, m), 7.54 (1H, d, J=9 Hz), 8.42 (1H, bs), 8.69 (1H, bs), 9.76 (1H, bs), 12.86 (1H, bs).
- 3-Aminosalicylic acid (690 mg, 4.51 mmol), methanol 5 (45 mL), and conc. sulfuric acid (0.9 mL) were mixed, and heated for 55 hours under reflux. The methanol was distilled off under reduced pressure. To the residue was added cooled water. The aqueous residue was made alkaline by addition of aqueous saturated sodium hydrogen carbonate under cooling with ice. Thus precipitated crystalline product were collected by filtration, washed with two portions of water, and dried in vacuo at 40° C. for 40 min., to give 710 mg of a pale pink crystalline product. The product was suspended in chloroform (35 mL), and insolubles were removed by filtration. The filtrate was dried over sodium sulfate and then concentrated under reduced pressure to give 181 mg (yield 25.9%) of the desired compound in the form of a brown crystalline product. 1H NMR (CDCl3, 400 MHz) δ: 3.88 (2H:, broad s), 3.94 (3H, s), 6.71 (1H, dd, J=8 Hz, 8 Hz), 6.87 (1H, d, J=8 Hz), 7.24 (1H, m), 10.88 (1H, s).
- (2) Methyl 3-(4-isobutoxy-3-nitrobenzoylamino)salicylate 4-Isobutoxy-3-nitrobenzoic acid (259 mg, 1.08 mmol) and methyl 3-aminosalicylate (181 mg, 1.08 mmol) were dissolved in dry dichloromethane (25 mL). WSC.HCl (207 mg, 1.08 mmol) was added to the resulting solution. The mixture was then stirred for 14 hours at room temperature. The solvent was distilled off at room temperature under reduced pressure. Water was added to the residue and the aqueous residue was subjected to extraction with, ethyl acetate. The ethyl acetate portion was successively washed with 2M hydrochloric acid, water, aqueous saturated sodium hydrogen carbonate, and aqueous saturated brine, and dried over sodium sulfate. The solvent was distilled off under reduced pressure, to give 320 mg of a brown oil. The obtained oil was subjected to silica gel column chromatography. The oil washed from the column with ethyl acetate/hexane (1/4) and then eluted using ethyl acetate/hexane (1/2), to give 115 mg (yield 27.4%) of the desired compound in the form of a white crystalline product.
- M.P.: 142-1440C.
- 1H NMR (CDCl3, 400 MHz) δ: 1.08 (6H, d, J=7 Hz), 2.115 2.3 (1H, m), 3.95 (2H, d, J=6 Hz), 3.99 (3H, s), 6.96 (1H, dd, J=8 Hz, 8 Hz), 7.16 (1H, d, J=9 Hz), 7.61 (1H, dd, J=2 Hz, 8 Hz), 8.09 (1H, dd, J=2 Hz, 9 Hz), 8.40 (1H, d, J=2 Hz), 8.51 (1H, broad s), 8.67 (1H, dd, J=2 Hz, 8 Hz), 11.40 (1H, s).
- IR (KBr, cm 1):3320, 1700, 1645, 1.620, 1545, 1530, 1435, 1340, 1270.
- Methyl 3-(4-isobutoxy-3-nitrobenzoylamino)salicylate (115 mg, 0.3 mmol) and phosphorus oxychloride (1.1 mL) were mixed and stirred at 110° C. for 4 hours. The stirred mixture was then cooled to room temperature, poured onto ice blocks, and extracted with ethyl acetate. The ethyl acetate portion was successively washed with water, aqueous saturated water, and aqueous saturated brine, and dried over sodium sulfate. The solvent was distilled off under reduced pressure, to give 97 mg of a pale yellow crystalline product. The obtained product was recrystallized from ethyl acetate (2 mL), to give 40 mg of the desired compound in the form of a white crystalline product. The mother liquor was concentrated, and the residue was recrystallized from ethyl acetate-hexane, to give 42 mg of the desired compound in the form of a white crystalline product. Total 82 mg (yield 73%)
- M.P.: 128-1290C
- 1H NMR (CDCl3) δ: 1.09 (6H, d, J=7 Hz), 2.1-2.3 (1H, m), 3.98 (2H, d, J=6 Hz), 4.07 (3H, s), 7.22 (1H, d, J=9 Hz), 7.44 (1H, dd, J=8 Hz, 8 Hz), 7.95 (1H, dd, J=1 Hz, 8 Hz), 8.01 (1H, dd, J=1 Hz, 8 Hz), 8.45 (1H, dd, J=2 Hz, 159 Hz), 8.75 (1H, d, J=2 Hz).
- IR (KBr, cm 1): 1720, 1625, 1520, 1345, 1315, 1300, 1285.
- Methyl 2-(4-isobutoxy-3-nitrophenyl)benzoxazole-7-carboxylate (22 mg, 0.06 mmol) was suspended in methanol (1.8 mL). Tetrahydrofuran (2.4 mL) and 1M NaOH (0.6 mL) were successively added to the suspension, and the mixture was stirred at 50° C. for 2 hours. A small amount of insoluble was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was suspended in water, made acidic by addition of 2M hydrochloric acid (0.6 mL), and extracted with ethyl acetate. The ethyl acetate portion washed successively with water and aqueous saturated brine, and dried over sodium sulfate. The solvent was distilled off under reduced pressure, to give 21 mg of a pale yellow crystalline product. The obtained product was recrystallized from ethyl acetate-hexane (4 mL-8 mL), to give 15 mg (yield 70%) of the desired compound in the form of a pale yellow crystalline product.
- M. P.:258-2600C.
- 1H NMR (CDCl3) δ: 1.10 (6H, d, J=7 Hz), 2.1-2.3 (1H, m), 3.99 (2H, d, J=6 Hz), 7.25 (1H, d, J=:9 Hz), 7.48 (1H, 10 dd, J=8 Hz, 8 Hz), 8.01 (1H, dd, J=1 Hz, 8 Hz), 8.07 (1H, dd, J=1 Hz, 8 Hz), 8.47 (1H, dd, J=2 Hz, 9 Hz), 8.78 (1H, d, J=2 Hz).
- 4-Isobutoxy-3-nitrobenzoic acid (240 mg, 1.00 mmol) and 3,4-diaminopyridine (153 mg, 1.40 mmol) were dissolved in dry DMF (10 mL). To the solution was added DCC (227 mg, 1.10 mmol) under cooling with ice. The solution was then stirred for 3 days at room temperature. Icewater (30 mL) was added, and the precipitated crystalline product was filtered, and washed with water (3 mL×3). The obtained residue was purified by silica gel column chromatography (methanol/chloroform=1/15), to give 13 mg (yield 4%) of an amide compound in the form of a pale brown crystalline product.
- Subsequently, 8 mg (0.024 mmol) of the amide product; was heated to 190° C. for 15 min, and allowed to stand to room temperature. The obtained crude product was subjected to thin layer chromatography (methanol/chloroform=1/10), to give 5 mg (yield 66%) of the desired compound in the form of a yellow crystalline product.
- 1H NMR (CDCl3/CD3OD=20/1, 400 MHz) δ: 1.09 (6H, d, J=7 Hz), 2.1-2.3 (1H, m), 3.97 (2H, d, J==7 Hz), 7.25 (1H, 5 d, J=9 Hz), 7.64 (1H, d, J=6 Hz), 8.30 (1H, d, J=6 Hz), 8.44 (1H, dd, J=2 Hz, 9 Hz), 8.66 (1H, d, J=2 Hz), 8.93 (1H, s).
- Ethyl 4-nitrobenzoate (50.0 g, 256 mmol) and potassium cyamide (51.2 g, 786 mmol) were added to DMSO (380 mL), stirred at 100° C. for 4 hours, and cooled to room temperature. DMSO was distilled off, and to the residue was added ice-water (200 mL). The aqueous residue washed with ethyl acetate (100 mL). To the mixture was added conc. hydrochloric acid, to change the pH of the mixture to 1. The mixture was then extracted with ethyl acetate (200 mL), washed with aqueous saturated brine (50 mL), dried over anhydrous sodium sulfate, and placed under reduced pressure to distill the solvent off. There was obtained 51.4 g of ethyl 3-cyano-4-hydroxybenzoate as a crude product.
- Isobutyl bromide (56.1 mL, 512 mmol) was added to a suspension of the ethyl 3-cyano-4-hydroxybenzoate crude product (51.4 g) and potassium carbonate (70.8 g, 512 mmol) in dry DMF (200 mL), stirred at 100° C. for 10 hours, and cooled to room temperature. Ice-water (500 mL) was then added to the cooled suspension. The aqueous mixture was extracted with ethyl acetate (200 mL×2). The ethyl acetate portion washed successively with water (500 mL×2) and aqueous saturated brine (200 mL), dried over anhydrous sodium sulfate, and placed under reduced pressure to distill the solvent off. The residue was purified by silica gel column chromatography (ethyl acetate/hexane=1/4). The resulting crystalline product was dissolved in ethyl acetate (50 mL) under heating. The mixture was kept hot, while hexane (100 mL) was added to the mixture. The hexane solution was stirred and cooled to room temperature, and further stirred for 10 min. under cooling with ice. The precipitated crystalline product was collected by filtration, washed successively with ethyl acetate/hexane (1/5, 60 mL) mixture and hexane (500 mL), and dried in air, to give 20.8 g (yield 33%) of the desired compound in the form of a pale yellow crystalline product.
- M.P.: 105.6-106.40C
- 1H NMR (CDCl3, 400 MHz) δ: 1.09 (6H, d, J=7 Hz), 1.39 (3H, t, J=7 Hz), 2.1-2.3 (1H, m), 3.90 (2H, d, J=7 Hz), 4.37 (2H, q, J=7 Hz), 6.98 (1H, d, J=9 Hz), 8.19 (1H, dd, J=2 Hz, 9 Hz), 8.25 (1H, d, J=2 Hz).
- Ethyl 3-cyano-4-isobutyloxybenzoate (20.0 g, 80.9 mmol) was dissolved in a mixture of ethanol (100 mL) and THF (100 mL). Aqueous 2M sodium hydroxide (45 mL, 90.0 mmol) was added to the resulting solution, and the mixture was stirred at 30° C. for 4 hours. The solvent was distilled off under reduced pressure. Water (100 mL) was added to the residue and further aqueous 2M hydrochloric acid to obtain an aqueous mixture of pH 1. The precipitated crystalline product was collected by filtration, washed with water (200 mL×2), and dried in air, to give 17.5 g (yield 99%) of the desired compound in the form of a white crystalline product.
- M.P.: 220.4-221.60C
- 1H NMR (CDCl3, 400 MHz) δ: 1.09 (6H, d, J=6 Hz), 2.1-2.3 (1H, m), 3.91 (2H, d, J=6 Hz), 7.00 (1H, d, J=9 Hz), 8.21 (1H, dd, J=2 Hz, 9 Hz), 8.27 (1H, d, J=2 Hz).
- A mixture of 3-amino-2-chlorobenzoic acid (500 mg, 2.91 mmol), conc. sulfuric acid (6 mL), and methanol (150 mL) was heated under reflux for 24 hours, and placed under reduced pressure to distill the solvent off. The residue was neutralized by addition of aqueous saturated sodium hydrogen carbonate. The neutralized mixture was extracted with toluene, dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off. There was obtained 497 mg (yield 92%) of the desired compound in the form of pale brown oil.
- 1H NMR (CDCl3, 500 MHz) δ: 3.91 (3H, s), 4.23 (2H, broad s), 6.89 (1H, dd, J=1 Hz, 8 Hz), 7.10 (1H, dd, J=8 Hz, 8 Hz), 7.16 (1H, dd, J=1 Hz, 8 Hz).
- Oxalyl chloride (889 mg, 7.0 mmol) was dropwise added to a solution of 3-cyano-4-isobutyloxybenzoic acid (767 mg, 3.5 mmol) in dichloromethane (10 mL) under cooling with ice. Subsequently, a catalytic amount of DMF was added. The mixture was then stirred for one hour at room temperature, heated under reflux for 3 hours, and placed under reduced pressure to distill the solvent off. Toluene was added to the residue and the solvent was distilled off under reduced pressure. THF (10 mL) was added to the residue. Further, a solution of methyl 3 amino-2-chlorobenzoate (497 mg, 2.68 mmol) and triethylamine (1.39 mL, 10 mmol) in THF (10 mL). The resulting mixture was stirred for 14 hours at room temperature, and toluene and aqueous 1M hydrochloric acid were added. The organic portion was taken out, washed with aqueous 1M hydrochloric acid and aqueous saturated sodium hydrogen carbonate, dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off.
- The residue was purified by silica gel column chromatography (ethyl acetate/toluene=1/20), to give 900 mg (purity 82%, yield 71%) of the desired compound as an oil.
- 1H NMR (CDCl3,500 MHz) δ: 1.06 (6H, d, J=6 Hz), 2.1-2.4 (1H, m), 3.87 (2H, d, J=6 Hz), 3.95 (3H, s), 6.93 (1H, d, J=9 Hz), 7.1-7.3 (2H, m), 7.83 (1H, dd, J=2 Hz, 8 Hz), 7.89 (1H, dd, J=2 Hz, 9 Hz), 7.98 (1H, d, J=2 Hz).
- A solution of methyl 2-chloro-3-(3-cyano-4-isobutyl-oxybenzoylamino) benzoate (1.07 g, purity 82%, 2.27 mmol) and Lawesson's reagent (1.23 g, 2.77 mmol) in toluene (20 mL) was heated under reflux for 5 hours, and placed under reduced pressure to distill the solvent off. The residue was purified by silica gel column chromatography (ethyl acetate/toluene=1/40), to give 670 mg (yield 73%) of the desired compound as an oil.
- 1H NMR (CDCl3, 500 MHz) δ: 1.09 (6H, d, J=7 Hz), 2.2-2.3 (11H, m), 3.92 (2H, d, J=7 Hz), 3.96 (3H, s), 7.01 (1H, d, J=9 Hz), 7.1-7.3 (1H, m), 7.43 (1H, dd, J=8 Hz, 8 Hz), 7.78 (1H, dd, J=1 Hz, 8 Hz), 8.10 (1H, d, J=9 Hz), 8.15 (1H, 5 d, J=1 Hz).
- A solution of methyl 2-chloro-3-(3-cyano-4-isobutyloxybenzoylamino) benzoate (670 mg, 1.66 mmol) in THF (5 mL) was dropwise added to a suspension of sodium hydride (200 mg, 4.98 mmol) in THF (5 mL) under cooling with ice. The mixture was stirred for 2 hours at room temperature, poured into ice-water, and extracted with toluene. The toluene portion was dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off. The residual crystalline product was recrystallized from hexane, to give 288 mg (yield 47%) of the desired compound in the form of a crystalline product.
- 1H NMR (CDCl3, 500 MHz) δ: 1.11 (6H, d, J=6 Hz), 2.1-2.3 (1H, m), 3.93 (2H, d, J=6 Hz), 4.05 (3H, s), 7.08 (1H, d, J=9 Hz), 7.59 (1H, dd, J=8 Hz, 8 Hz), 8.13 (1H, dd, J=2 Hz, 8 Hz), 8.24 (1H, dd, J=2 Hz, 8 Hz), 8.27 (1H, dd, J=2 Hz, 9 Hz), 8.39 (1H, d, J=2 Hz).
- Methyl 2-(3-cyano-4-isobutyloxyphenyl)-1,3-benzothiazole-carboxylate (288 mg, 0.786 mmol) was dissolved in a mixed solvent (50 mL) of methanol/ethanol/THF (2/1/2), and, then a solution of potassium hydroxide (281 mg, 5 mmol) in water (10 mL) was added and stirred for one hour at room temperature. The mixture was made acidic by addition of aqueous 1M hydrochloric acid, and placed under reduced pressure to distill the solvent off. The residue was extracted with chloroform. The chloroform portion was then dried over anhydrous magnesium sulfate and placed under reduced pressure too distill the solvent off. The residual crystalline product was recrystallized from toluene, to give 230 mg (yield 83%) of the desired compound in the form of a white crystalline product.
- M.p.: 268-270° C.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.04 (6H, d, J=7 Hz), 2.0-2.2 (1H, m), 4.05 (2H, d, J=7 Hz), 7.44 (1H, d, J=9 Hz), 7.69 (1H, dd, J=8 Hz, 8 Hz), 8.10 (1H, dd, J=1 Hz, 8 Hz), 8.30 (1H, dd, J=1 Hz, 8 Hz), 8.41 (1.H, dd, J=2 Hz, 9 Hz), 8.47 (1H, d, J=2 Hz).
- IR (KBr, cm−1): 2966, 2875, 1608, 1518, 1477, 1471, 1396, 1306, 1282, 1240, 1238, 1211, 1155, 1009.
- 3-Nitrobenzoic anhydride (9.65 g, 50 mmol) was divided into three portions and added by portions to aqueous ammonia (28%) under cooling with ice. The mixture was stirred at 60° C. for 12 hours, and placed under reduced pressure to distill the solvent off. The residue was made acidic by addition of aqueous 12M hydrochloric acid. The precipitated crystalline product was collected by filtration, washed with water, and dried in air, to give 9.86 g (yield 94%) of the desired compound in the form of a white crystalline product.
- 1H NMR (DMSO-d6, 400 MHz) δ: 7.65 (1H, broad s), 7.78 5 (1H, dd, J=8 Hz, 8 Hz), 8.06 (1H, broad s), 8.18 (1H, dd, J=1 Hz, 8 Hz), 8.24 (1H, dd, J=1 Hz, 8 Hz).
- Bromine (2.56 mL, 48 mmol) was dropwise added to an aqueous potassium hydroxide solution (24.1 g, 430 mmol in 110 mL) under cooling with ice. The resulting solution was added to 3-nitrophthalamine (9.86 g, 47 mmol), and the mixture was stirred at 60° C. for 3 hours, and then stirred for 12 hours at room temperature. The precipitated orange crystalline product was collected by filtration, dissolved in water (50 ml), and made acidic by addition of aqueous 6M hydrochloric acid. The precipitated crystalline product was collected by filtration, washed with several portions of water, and dried in air, to give 6.0 g (yield 70%) of the desired compound in the form of a yellow crystalline product.
- Thionyl chloride (14.6 mL, 200 mmol) was dropwise added to methanol (150 mL) under cooling with ice. The resulting solution was added 3-nitroanthranilic acid (3.65 g, 20 mmol), heated under reflux for 23 hours, and then placed under reduced pressure to distill the solvent off. To the residue were added toluene and aqueous saturated sodium hydrogen carbonate. The organic portion was taken out, dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off.
- There was obtained 2.68 g (yield 68) of the desired compound in the form of a yellow crystalline product.
- 1H NMR (CDCl3, 500 MHz) δ: 3.92 (3H, s), 6.66 (1H, dd, J=8 Hz, 8 Hz), 8.24 (1H, dd, J=2 Hz, 8 Hz), 8.38 (1H, dd, 5 J=2 Hz, 8 Hz).
- To a solution of methyl 3-nitroanthranilate (1.44 g, 7.34 mmol) in methanol (50 mL) was added 10% Pd/C (300 mg), and the resulting mixture was stirred for 12 hours at room temperature under hydrogen atmosphere. The 10% Pd/C was removed, and the solvent was distilled off under reduced pressure, to give 1.22 (quantitative yield) of the desired compound in the form of a brown crystalline product.
- Thionyl chloride (3.06 mL, 42 mmol) and a catalytic amount of DMF were successively added to a solution of 3cyano-4-isobutyloxybenzoic acid (1.53 g, 7.0 mmol) in dichloromethane (15 mL). The mixture was heated under reflux for 4 hours, and placed under reduced pressure to distill the solvent off. To the residue was added THF (20 mL) under cooling with ice. The residue solution was then dropwise added to a solution of methyl 3-amino anthranilate (1.22 g, 7.34 mmol) and triethylamine (2 mL) in THF (20 mL), and the mixture was stirred at 45° C. for 5 hours. The precipitated crystalline product was collected by filtration and washed with several portions of ethyl acetate, to give 2.11 g (yield 82%) of the desired compound in the form of a pale green crystalline product.
- 1H NMR (DMSO-d6, 500 MHz) δ: 1.03 (6H, d, J=7 Hz), 2.0-2.2 (1H, m), 3.82 (3H, s), 4.02 (2H, d, J=7 Hz), 6.5-6.7 (3H, m), 7.35 (1H, dd, J=2 Hz, 8 Hz), 7.39 (1H, d, J=9 Hz), 7.72 (1H, dd, J=2 Hz, 8 Hz), 8.25 (1H, dd, J=2 Hz, 59 Hz), 8.41 (1H, d, J=2 Hz), 9.74 (1H, S).
- A solution of methyl 3-(3-cyano-4-isobutyloxybenzoylamino)anthranilate (341 mg, 0.93 mmol) in glacial acetic acid (10 mL) was heated under reflux for 2 hours, cooled, and placed under reduced pressure to distill the solvent off. To the residue was added a solution of sodium hydroxide (240 mg, 10 mmol) in methanol (20 mL), and the mixture was stirred for 5 hours at room temperature. The reaction mixture was made acidic by addition of aqueous 1M hydrochloric acid, and placed under reduced pressure to distill the solvent off. To the residue were added ethyl acetate and water. The organic portion was taken out, dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off. The residue washed with hot toluene, to give 300 mg (yield 960) of the desired compound in the form of a pale yellow crystalline product.
- M.p.: 299-302° C.
- 1H NMR (DMSO-d6, 400 MHz) δ: 1.04 (6H, d, J=7 Hz), 2.0-2.2 (1H, m), 4.03 (2H, d, J=7 Hz), 7.32 (1H, dd, J=8 Hz, 8 Hz), 7.42 (1H, d, J=9 Hz), 7.82 (1H, d, J=8 Hz), 7.91 (1H, d, J=8 Hz), 8.58 (1H, dd, J=2 Hz, 9 Hz), 8.79 (1H, broad s), 12.46 (1H, broad s), 13.48 (1H, broad s).
- IR (KBr, cm−1): 3319, 1500, 1498, 1433, 1302, 1281, 1238, 1209, 1147, 762.
- (1) 3-Cyano-4-isobutyloxy-N-(3-methoxyphenyl)benzamide Dichloromethane (20 mL) was added to a mixture of 3cyano-4-isobutyloxybenzoic acid (2.19 g, 10 mmol), m-anisidine (1.85 g, 15 mmol), 1-[3-(dimethylamino)propyl]3-ethylcarbodiimide hydrochloride (WSC.HCl, 3.83 g, 20 mmol), and 4-(dimethylamino)pyridine (244 mg, 2.0 mmol). The resulting mixture was then stirred for 21 hours at room temperature. To the mixture was added aqueous 1M hydrochloric acid (30 mL), and the resulting mixture was extracted with ethyl acetate (40 mL). The ethyl acetate portion washed with aqueous saturated sodium hydrogen carbonate, dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off. The residue was recrystallized from toluene, to give 2.87 g (yield 89%) of the desired compound in the form of a crystalline product.
- 1H NMR (CDCl3, 500 MHz) δ: 1.09 (6H, d, J=6 Hz), 2.1-2.3 (1H, m), 3.83 (3H, s), 3.90 (2H, d, J=6 Hz), 6.72 (1H, dd, J=1 Hz, 8 Hz), 7.03 (1H, d, J=8 Hz), 7.12 (1H, dd, J=1 Hz, 8 Hz), 7.2-7.3 (1H, m), 7.40 (1H, dd, J=2 Hz, 2 Hz), 7.92 (1H, broad s), 8.0-8.2 (1H, m).
- A solution of 3-cyano-4-isobutyloxy-N-(3-methoxyphenyl)benzamide (972 mg, 3.0 mmol) and Lawesson's reagent (808 mg, 2.0 mmol) in toluene (5 mL) was heated under reflux for 3.5 hours. After addition of toluene (approx. 20 mL), the heated solution was allowed overnight to lapse at room temperature. The precipitated crystalline product was collected by filtration, to give 900 mg (yield 88%) of the desired compound in the form of a yellow crystalline product.
- 1H NMR (CDCl3, 500 MHz) δ: 1.08 (6H, d, J=7 Hz), 2.1-2.3 (1H, m), 3.83 (3H, s), 3.89 (2H, d, J=7 Hz), 6.8-7.0 (2H, m), 7.0-7.8 (2H, m), 7.8-8.2 (2H, m), 8.8-8.6 (1H, m).
- Dioxane (70 mL) and water (70 mL) were added to a mixture of 3-cyano-4-isobutyloxy-N-(3-methoxyphenyl)thiobenzamide (900 mg, 2.64 mmol), potassium ferricyanide (2.61 g, 7.93 mmol), and potassium hydroxide (892 mg, 15.9 mmol). The resulting mixture was stirred for 20 hours at room temperature. The mixture was then placed under reduced pressure to distill the solvent off, and extracted with ethyl acetate (50 mL). The ethyl acetate portion washed with water, dried over anhydrous magnesium sulfate, and placed under reduced pressure to distill the solvent off. The residue was purified by silica gel column chromatography (ethyl acetate/toluene=1/20-1/10), to give 322 mg (yield 36%) of the desired compound in the form of a pale yellow crystalline product.
- 1H NMR (CDCl3, 500 MHz) δ: 1.10 (6H, d, J=6 Hz), 2.1-2.3 (1H, m), 3.92 (2H, d, J=6 Hz), 4.02 (3H, s), 6.85 (1H, 30 d, J=8 Hz), 7.06 (1H, d, J=9 Hz), 7.45 (1H, dd, J=8 Hz, 8 Hz), 7.68 (1H, d, J=8 Hz), 8.23 (1H, dd, J=2 Hz, 9 Hz), 8.30 (1H, d, J=2 Hz).
- Ethane thiol (0.45 mL, 6.08 mmol) was added to lithium metal (14 mg, 2.02 mmol), and the mixture was stirred for one hour at room temperature. To tire mixture were then added dry DMF (5 mL) and 2-(3-cyano-4-isobutyloxyphenyl)-7-methoxy-1,3-benzothiazole (150 mg, 0.44 mmol). The resulting mixture was stirred at 80° C. for 8.5 hours, cooled to room temperature, and, after addition of icewater (10 mL), made to pH 7 by addition of aqueous 1M hydrochloric acid. The mixture was then extracted with ethyl acetate (20 mL). The ethyl acetate portion washed successively with water (10 mL) and aqueous saturated brine (10 mL), dried over anhydrous sodium sulfate, and placed under reduced pressure to distill the solvent off. The residue was purified by silica, gel column chromatography (ethyl acetate/hexane=1/3), and suspended in hexane. The obtained crystalline product was collected by filtration, washed with hexane, and dried in air, to give 17 mg (yield 12%) of the desired compound in the form of a pale yellow crystalline product.
- M.p.: 200-202° C.
- hu 1H NMR (DMSO-d6, 400 MHz) δ: 1.04 (6H, d, J=6 Hz), 2.0-2.2 (1H, m), 4.03 (2H, d, J=6 Hz), 6.87 (1H, d, J=8 Hz), 7.36 (1H, dd, J=8 Hz, 8 Hz), 7.42 (1H, d, J=9 Hz), 7.51 (1H, d, J=8 Hz), 8.33 (1H, dd, J=2 Hz, 9 Hz), 8.38 (1H, d, J=2 Hz).
- IR (KBr, cm−:L): 3319, 2960, 2873, 2231, 1579, 1470, 1392, 1281, 1022, 787.
- 1. Preparation of Test Sample
- The test compound was dissolved in dimethylsulfoxide and diluted with 50 mM phosphate buffer (pH 7.5), to give a solution of a predetermined concentration
- 2. Measurement
- 250 gL of each of the solutions of the test compound having different concentrations was added to 1 mL of a solution of Xanthine (SIGMA, 300 μM) in the 50 mM phosphor buffer (pH 7.5). The mixture was then pre-incubated at 37° C. for 10 min. Subsequently, to the pre-incubated mixture was added 250 mL of Cow milk Xanthine Oxidase (Roche) diluted with the 50 mM phosphate buffer (pH 7.5) to give a solution of 30 mU concentration. The mixture was then kept at 37° C. for 15 min for performing a reaction. The reaction was terminated by addition of 1N hydrochloric acid. Subsequently, the absorbance (OD 290 mm) was measured by means of a spectrophotometer (HITACHI U-2000), to obtain the inhibition ratio.
- The inhibition ratio was calculated according to the following fommula:
Inhibition ratio(%)=[1−(B−C)/(A−C)]×100 - A: absorbance of control
- B: absorbance measured in the case of using test compound
- C: absorbance of blank
- 3. Test Results
- The test results are set forth in Table 20.
TABLE 20 Example number IC50 (nM) Example 1-A 63.2 Example 1-B 44.8 Example 2 11.1 Example 6 75.9 Example 7 102.0 Example 8 18.6 Example 9 58.4 Example 10 50.0 Example 11 22.3 Example 12 161.3 Allopurinol 542.1 - As is apparent from Table 20, the compounds of the present invention show a xanthine oxidase inhibiting action superior to allopurinol.
- 1. Test Animals, and Grouping
- ICR mouse (Japan Charles River Co., Ltd., 6 W) was employed as test animal. One group comprised mice, and a vehicle control group was set for each experiment.
- 2. Preparation and Administration of the Test Compound
- The test compound was suspended in aqueous 0.50 methylcellulose solution to for administration.
- Dosage is 3 mg/10 mL/kg for each of the control groups and all test groups. The administration was made by single oral administration.
- 3. Procedure of Experiment
- The test compound was orally administered once, and the whole blood was collected from main artery in the presence of heparin after one hour. From the collected whole blood was separated plasma in the conventional manner, and the plasma was subjected to measurement of uric acid value by the enzyme method by means of an automatic analytical apparatus (HITACHI 7060E).
- The inhibition ratio was calculated according to the following formula:
Inhibition ratio(%)=(100−A/B)×100 - A: average uric acid value in plasma of the group into which the test compound was administered.
- B: average uric acid value in plasma of the vehicle control group
- 4. Test Results
- Test results are set forth in Table 21.
TABLE 21 Example number Inhibition ratio (%) Example 1-B 60.7 Example 6 63.8 Example 8 56.8 Example 10 56.1 Example 11 51.4 - As is apparent from Table 21, the compounds of the present invention show a significant xanthine oxidase inhibiting action even in the experiment of in vivo.
Claims (12)
1. Compounds of the following formula (I) or salts thereof
in which
R1 represents an alkyl group having 1-8 carbon atoms, an alkyl group substituted
with 1-3 halogen atoms, OR4, CO2R5, or S(O), nR6; wherein R4 is hydrogen, or an alkyl group having 1-8 carbon atoms, an aralkyl group having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms, an alkylcarbonyl group having 2-9 carbon atoms, an arylcarbonyl group having an aryl moiety of 6-10 carbon atoms, an aralkylcarbonyl group having an aryl moiety of 6-10 carbon atoms and an alkylcarbonyl moiety of 2-5 carbon atoms or an aryl group having 6-10 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro and cyano; each of R5 and R6 is hydrogen or an alkyl group having 1-8 carbon atoms, an aralkyl group having an aryl moiety of 6-10 carbon atoms and an alkyl moiety of 1-4 carbon atoms, or an aryl group having 6-10 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; and n is an integer of 0 to 2;
R2 is hydrogen, halogen, nitro, cyano, formyl, an alkyl group having 1-8
carbon atoms, an alkyl group having 1-8 carbon atoms which is substituted with one to three halogens, or CO2R7 wherein R7 has the same meaning as R5 above;
R3 is hydrogen, halogen, hydroxyl, amino, CO2R8, PO3H, PO(OH)(OR′),
S(O)mR10, or an alkyl group having 1-8 carbon atoms or an alkylaminocarbonyl group having alkyl of 1-8 carbon atoms which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; wherein each of R8, R9, and R10 has the same meaning as R5 above; m has the same meaning as n above;
X is NR11, oxygen, or sulfur, wherein R11 is hydrogen, or an alkyl group having
1-8 carbon atom which may have a substituent selected from the group consisting of halogen, hydroxyl, nitro, cyano and amino; and
each of Y and Z is CR12 or nitrogen, wherein R12 has the same meaning as R3 above.
2. The compounds or salts thereof according to claim 1 , wherein R1 is OR4.
3. The compounds or salts thereof according to claim 1 , wherein R1 is an alkoxy group having 1-5 carbon atoms.
4. The compounds or salts thereof according to claim 1 , wherein R1 is isobutoxy.
5. The compounds or salts thereof according to one of claims 1-4, wherein R2 is nitro, cyano, halogen, or carboxyl.
6. The compounds or salts thereof according to one of claims 1-4, wherein R2 is nitro or cyano.
7. The compounds or salts thereof according to one 10 of claims 1-6, wherein R3 is hydrogen, amino, hydroxyl, halogen, or carboxyl.
8. The compounds or salts thereof according to one of claims 1-7, wherein X is NH or oxygen, and each of Y and Z are nitrogen.
9. The compounds or salts thereof according to one of claims 1-7, wherein X is sulfur, oxygen, or NH, Y is CH, C—OH, or C—CO2H, and Z is CH.
10. The compounds or salts thereof according to one of claims 1-7, wherein X is NH, and one of Y and Z is nitrogen and other is CH.
11. A xanthine oxidase inhibitor containing as an active ingredient the compound or a salt thereof according to one of claims 1-10.
12. An agent for treating hyperuricemia containing as an active ingredient the compound or a salt thereof according to one of claims 1-10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/829,286 US20070265283A1 (en) | 2001-11-16 | 2007-07-27 | Xanthine Oxidase Inhibitor |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001352340 | 2001-11-16 | ||
JP2001-352340 | 2001-11-16 | ||
US10/495,844 US7253154B2 (en) | 2001-11-16 | 2002-11-14 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors |
PCT/JP2002/011893 WO2003042185A1 (en) | 2001-11-16 | 2002-11-14 | Xanthine oxidase inhibitors |
US11/829,286 US20070265283A1 (en) | 2001-11-16 | 2007-07-27 | Xanthine Oxidase Inhibitor |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/495,844 Division US7253154B2 (en) | 2001-11-16 | 2002-11-14 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors |
PCT/JP2002/011893 Division WO2003042185A1 (en) | 2001-11-16 | 2002-11-14 | Xanthine oxidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070265283A1 true US20070265283A1 (en) | 2007-11-15 |
Family
ID=19164532
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/495,844 Expired - Lifetime US7253154B2 (en) | 2001-11-16 | 2002-11-14 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors |
US11/829,286 Abandoned US20070265283A1 (en) | 2001-11-16 | 2007-07-27 | Xanthine Oxidase Inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/495,844 Expired - Lifetime US7253154B2 (en) | 2001-11-16 | 2002-11-14 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors |
Country Status (11)
Country | Link |
---|---|
US (2) | US7253154B2 (en) |
EP (1) | EP1452528B1 (en) |
JP (2) | JP4634037B2 (en) |
KR (1) | KR100919147B1 (en) |
CN (2) | CN101092400A (en) |
AT (1) | ATE404541T1 (en) |
DE (1) | DE60228316D1 (en) |
DK (1) | DK1452528T3 (en) |
ES (1) | ES2309213T3 (en) |
PT (1) | PT1452528E (en) |
WO (1) | WO2003042185A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070293512A1 (en) * | 2004-06-14 | 2007-12-20 | Shinichi Yoshida | Condensed Pyrimidine Deriviative and Xanthine Oxidase Inhibitor |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1587821T1 (en) * | 2002-12-19 | 2009-02-28 | Scripps Research Inst | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
WO2005105803A2 (en) * | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
KR101191071B1 (en) | 2004-06-14 | 2012-10-15 | 닛뽕 케미파 가부시키가이샤 | Condensed pyrimidine derivative and xanthine oxidase inhibitor |
US8557831B2 (en) * | 2004-07-21 | 2013-10-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
CN101248074A (en) * | 2005-07-01 | 2008-08-20 | 日本化学医药株式会社 | Xanthine oxidase inhibitor |
EP3219319A1 (en) * | 2006-06-22 | 2017-09-20 | Nippon Chemiphar Co., Ltd. | Agent for overcoming resistance to anti-cancer agent |
EP2074223A4 (en) * | 2006-09-15 | 2010-03-10 | Foldrx Pharmaceuticals Inc | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins |
WO2008126899A1 (en) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | 5-membered heterocyclic derivative and use thereof for medical purposes |
EP2165705A1 (en) | 2008-09-18 | 2010-03-24 | Centre National de la Recherche Scientifique (CNRS) | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
JP5673008B2 (en) | 2010-08-11 | 2015-02-18 | ソニー株式会社 | Image processing apparatus, stereoscopic image display apparatus and stereoscopic image display system, parallax deviation detection method for stereoscopic image display apparatus, and manufacturing method for stereoscopic image display apparatus |
CN102095825B (en) * | 2010-12-08 | 2014-07-23 | 中国科学院长春应用化学研究所 | Method for screening xanthine oxidase inhibitor by ultra performance liquid chromatography and mass spectrometry |
RU2586330C2 (en) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Solid forms of transthyretin dissociation inhibitor |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
LT3083627T (en) | 2013-12-19 | 2018-12-27 | Novartis Ag | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |
JP2017048116A (en) * | 2014-01-10 | 2017-03-09 | 国立研究開発法人国立国際医療研究センター | Pulmonary hypertension therapeutic agent |
WO2016136727A1 (en) * | 2015-02-24 | 2016-09-01 | 国立大学法人鳥取大学 | Drug for preventing and/or treating dementia |
CN106146533B (en) * | 2016-07-14 | 2018-04-03 | 华润赛科药业有限责任公司 | Sulfur heterocyclic ring carboxylic acid derivative, its preparation method and application |
WO2020009374A1 (en) * | 2018-07-04 | 2020-01-09 | 고려대학교 세종산학협력단 | Novel 4-substituted oxazoloquinolinone derivatives, pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of allergic diseases including asthma or atopic dermatitis comprising same |
CN110283137A (en) * | 2019-06-13 | 2019-09-27 | 爱斯特(成都)生物制药股份有限公司 | A kind of preparation method of 2- (4- bromophenyl) -1,3- benzoxazoles |
CN111620833A (en) * | 2020-06-05 | 2020-09-04 | 青岛伯川特聚科技有限公司 | Preparation method of 2-phenylbenzoxazole compound |
CN113004188B (en) * | 2021-03-16 | 2022-09-20 | 沈阳药科大学 | Indole derivative, preparation method and application |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
DE2927988A1 (en) * | 1979-07-11 | 1981-02-05 | Thomae Gmbh Dr K | NEW 8-PHENYL PURINS, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
ZA832938B (en) | 1982-05-03 | 1984-12-24 | Lilly Co Eli | 2-phenylimidazo(4,5-c)pyridines |
JPS62246581A (en) * | 1986-04-17 | 1987-10-27 | Chugai Pharmaceut Co Ltd | Furobenzoxazole derivative |
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
JPH03258770A (en) | 1990-03-08 | 1991-11-19 | Tanabe Seiyaku Co Ltd | Benzazole derivative, preparation thereof and synthetic intermediate theroef |
JP3176073B2 (en) * | 1990-06-19 | 2001-06-11 | キヤノン株式会社 | Liquid crystal element |
BR0111564A (en) | 2000-06-14 | 2003-04-29 | Warner Lambert Co | Indole and benzimidazole as 15-lipoxygenase inhibitors |
JP2004503553A (en) * | 2000-06-14 | 2004-02-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 6,5-fused bicyclic heterocycle |
GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
-
2002
- 2002-11-14 CN CNA2007101369545A patent/CN101092400A/en active Pending
- 2002-11-14 JP JP2003544021A patent/JP4634037B2/en not_active Expired - Fee Related
- 2002-11-14 DK DK02780099T patent/DK1452528T3/en active
- 2002-11-14 AT AT02780099T patent/ATE404541T1/en active
- 2002-11-14 KR KR1020047007333A patent/KR100919147B1/en active IP Right Grant
- 2002-11-14 EP EP02780099A patent/EP1452528B1/en not_active Expired - Lifetime
- 2002-11-14 US US10/495,844 patent/US7253154B2/en not_active Expired - Lifetime
- 2002-11-14 DE DE60228316T patent/DE60228316D1/en not_active Expired - Lifetime
- 2002-11-14 CN CNB028272056A patent/CN100338040C/en not_active Expired - Fee Related
- 2002-11-14 ES ES02780099T patent/ES2309213T3/en not_active Expired - Lifetime
- 2002-11-14 PT PT02780099T patent/PT1452528E/en unknown
- 2002-11-14 WO PCT/JP2002/011893 patent/WO2003042185A1/en active IP Right Grant
-
2007
- 2007-07-27 US US11/829,286 patent/US20070265283A1/en not_active Abandoned
-
2010
- 2010-04-06 JP JP2010088128A patent/JP5297414B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070293512A1 (en) * | 2004-06-14 | 2007-12-20 | Shinichi Yoshida | Condensed Pyrimidine Deriviative and Xanthine Oxidase Inhibitor |
US7598254B2 (en) * | 2004-06-14 | 2009-10-06 | Nippon Chemiphar Co., Ltd. | Substituted 1,3-thiazolo[5,4-d]pyrimidines as xanthine oxidase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US7253154B2 (en) | 2007-08-07 |
KR20040065223A (en) | 2004-07-21 |
JP4634037B2 (en) | 2011-02-16 |
ATE404541T1 (en) | 2008-08-15 |
JPWO2003042185A1 (en) | 2005-03-10 |
CN1615299A (en) | 2005-05-11 |
US20050090472A1 (en) | 2005-04-28 |
EP1452528A4 (en) | 2005-11-16 |
EP1452528A1 (en) | 2004-09-01 |
EP1452528B1 (en) | 2008-08-13 |
DK1452528T3 (en) | 2008-11-10 |
ES2309213T3 (en) | 2008-12-16 |
DE60228316D1 (en) | 2008-09-25 |
WO2003042185A1 (en) | 2003-05-22 |
JP2010180232A (en) | 2010-08-19 |
PT1452528E (en) | 2008-10-14 |
CN100338040C (en) | 2007-09-19 |
KR100919147B1 (en) | 2009-09-25 |
CN101092400A (en) | 2007-12-26 |
JP5297414B2 (en) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070265283A1 (en) | Xanthine Oxidase Inhibitor | |
US6710055B2 (en) | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions | |
US5840891A (en) | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | |
US6414008B1 (en) | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions | |
EP1757610B1 (en) | Condensed pyrimidine derivative and xanthine oxidase inhibitor | |
EP0966454A1 (en) | Disubstituted bicyclic heterocycles, their production and use as medicaments | |
HRP20030081A2 (en) | Benzimidazole derivatives, preparation and therapeutic use thereof | |
TW200404803A (en) | Novel use | |
IL114735A (en) | L-monovaline ester of 2-2-amino-1, 6-dihydro-6- oxopurin-9-yl) methoxy- 3-hydroxy-1-propanol, its preparation and pharmaceutical compositions containing it | |
CN102807568B (en) | Thiadiazoles derivative class DPP-IV inhibitor | |
PL172904B1 (en) | 7-(2-aminothety)-benzothiazolones and method of obtaining them | |
US20090149452A1 (en) | Xanthine oxidase inhibitor | |
US5158953A (en) | 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof | |
JPH07309872A (en) | Fused-ring pyrimidine derivative and analgesic agent | |
JPH10505330A (en) | Halogen imidazopyridine | |
JPS60181081A (en) | Novel bisbenzofuranyl ketone derivative and its preparation | |
JP2597731B2 (en) | N- (2-hydroxyethyl) -3- (4-nitrophenyl) propylamine and method for producing the same | |
KR100290533B1 (en) | Antiviral 2-aminopurine acyclonucleocside derivatives | |
JPH03232885A (en) | Quinazoline derivate and its salt | |
JPH0517480A (en) | Condensed imidazole derivative | |
JPH07267963A (en) | Tetracyclic compound | |
JPS60130591A (en) | Cephalosporins | |
PL198759B1 (en) | Novel benzimidazoles and benzoxazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |